Blood Test Detects Brain Metastases While Treatable
By LabMedica International staff writers Posted on 16 Aug 2017 |
Image: The model illustrates clinical implications of BCBM CTC screening method for brain micro-metastasis before they become detectable by MRI. BCBM-associated CTCs can be used as a tool to evaluate responses to therapy for BCBM patients (Photo courtesy of Houston Methodist).
A blood test is being generated that can identify breast cancer patients who are at increased risk for developing brain metastasis, and also monitor disease progression and response to therapy in real time.
According to extensive clinical studies, approximately 20% of breast cancer patients will develop brain metastasis over their lifetime, and, in general, metastatic disease to the brain is estimated to become the number one cancer killer within the next decade.
Scientists at Houston Methodist Hospital (Houston, TX, USA) and their colleagues collected blood samples were from advanced-stage breast cancer patients and blood samples from healthy female donors. Under strict aseptic conditions, 10 to 30 mL peripheral blood was obtained (first 5 ml were not used to avoid possible contamination by normal skin cells) and stored in tubes containing CellSave or EDTA, depending on downstream application.
For multi-parametric flow cytometry and Silicon Biosystems’ DEPArray, various primary antibodies were used. For Epithelial cell adhesion molecule (EpCAM)-positive circulating tumor cells (CTC) capture and enumeration by CellSearch, 7.5 mL of peripheral blood was collected in CellSave tubes per CTC assay procedures, and was processed using the Silicon Biosystems’ Cellsearch platform. For CTC isolation by multi-parametric flow cytometry, peripheral blood from breast cancer patients was analyzed and sorted using the FACSAriaII. The scientists also performed immuno-cytochemistry, genomic and mRNA characterization of isolated CTCs, RNA microarrays and pathway analyses.
The investigators found that breast cancer brain metastasis (BCBM) CTCs is enriched in a distinct sub-population of cells identifiable by their biomarker expression and mutational content. Deriving from a comprehensive analysis of CTC transcriptomes, they discovered a unique “circulating tumor cell gene signature” that is distinct from primary breast cancer tissues. Further dissection of the circulating tumor cell gene signature identified signaling pathways associated with BCBM CTCs that may have roles in potentiating BCBM.
Dario Marchetti, PhD, the senior author of the study, said, “Our lab is the first in this field to perform a comprehensive report of patient-derived circulating tumor cells at the gene expression level, so we now have a clearer picture of the signaling pathways that allows them to establish brain metastases. By comparing the whole genome expression patterns of CTCs isolated from patient blood samples diagnosed with or without BCBM, we uncovered a 126 gene-signature that is specific to these brain metastatic CTCs.” The study was published on August 4, 2017, in the journal Nature Communications.
Related Links:
Houston Methodist Hospital
According to extensive clinical studies, approximately 20% of breast cancer patients will develop brain metastasis over their lifetime, and, in general, metastatic disease to the brain is estimated to become the number one cancer killer within the next decade.
Scientists at Houston Methodist Hospital (Houston, TX, USA) and their colleagues collected blood samples were from advanced-stage breast cancer patients and blood samples from healthy female donors. Under strict aseptic conditions, 10 to 30 mL peripheral blood was obtained (first 5 ml were not used to avoid possible contamination by normal skin cells) and stored in tubes containing CellSave or EDTA, depending on downstream application.
For multi-parametric flow cytometry and Silicon Biosystems’ DEPArray, various primary antibodies were used. For Epithelial cell adhesion molecule (EpCAM)-positive circulating tumor cells (CTC) capture and enumeration by CellSearch, 7.5 mL of peripheral blood was collected in CellSave tubes per CTC assay procedures, and was processed using the Silicon Biosystems’ Cellsearch platform. For CTC isolation by multi-parametric flow cytometry, peripheral blood from breast cancer patients was analyzed and sorted using the FACSAriaII. The scientists also performed immuno-cytochemistry, genomic and mRNA characterization of isolated CTCs, RNA microarrays and pathway analyses.
The investigators found that breast cancer brain metastasis (BCBM) CTCs is enriched in a distinct sub-population of cells identifiable by their biomarker expression and mutational content. Deriving from a comprehensive analysis of CTC transcriptomes, they discovered a unique “circulating tumor cell gene signature” that is distinct from primary breast cancer tissues. Further dissection of the circulating tumor cell gene signature identified signaling pathways associated with BCBM CTCs that may have roles in potentiating BCBM.
Dario Marchetti, PhD, the senior author of the study, said, “Our lab is the first in this field to perform a comprehensive report of patient-derived circulating tumor cells at the gene expression level, so we now have a clearer picture of the signaling pathways that allows them to establish brain metastases. By comparing the whole genome expression patterns of CTCs isolated from patient blood samples diagnosed with or without BCBM, we uncovered a 126 gene-signature that is specific to these brain metastatic CTCs.” The study was published on August 4, 2017, in the journal Nature Communications.
Related Links:
Houston Methodist Hospital
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans